Live Nasdaq Composite: Markets Take Breather After Impressive Q2 Showing on Easing Oil Outlook

Health and Healthcare

Bristol Myers Squibb : BMY

All Bristol Myers Squibb Articles

592 Articles

Paul Ausick | Jul 18, 2012 at 10:56 AM EDT

Top 10 U.S. Drugs for 2012 First Quarter

Online drug research firm drugs.com today released its list of the top 100 selling drugs in the United States for…

Paul Ausick | Jul 18, 2012 at 8:34 AM EDT

Abbott Labs Stung by Foreign Exchange Rate

Abbott Laboratories (NYSE: ABT) reported second-quarter results this morning that beat the consensus estimate for earnings per share (EPS), but…

Jon C. Ogg | Jul 16, 2012 at 10:43 AM EDT

Looking for the Next Biotech Buyout After Two Drug and Biotech Deals

What usually happens when you get two mergers announced in drugs and biotech in the same day? Investors begin to…

Jon C. Ogg | Jul 10, 2012 at 7:35 AM EDT

Finding the Next Biotech M&A Targets (HGSI, GSK, AMLN, BMY, VRTX, CELG, CBST, AMRN, DNDN, BMRN, VVUS, ARNA, PCYC, VICL, MDGN, AFFX, THRX, RIGL)

More biotech mergers are on the way! That is the verdict of Wall St. There may be patent protection risks…

Jon C. Ogg | Jul 2, 2012 at 2:42 PM EDT

Which Biotechs Could Be Next M&A Targets (AMLN, BMY, VRTX, CELG, CBST, AMRN, BMRN, VVUS, ARNA, PCYC, AFFX, THRX, RIGL, HGSI, GSK, DNDN)

The freshly announced multibillion biotech buyout of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) for more than $5 billion in equity value…

Jon C. Ogg | Jul 2, 2012 at 8:14 AM EDT

The Next Mergers & Buyouts For 2012

As of late last week we had many potentially imminent buyouts that could have hit the market. When we were…

Jon C. Ogg | Jun 30, 2012 at 9:45 AM EDT

The Long Buyout Valuation of Amylin… A Higher Price Yet To Come?

Some mergers are very straight-forward, and others are just odd. Now we have an answer over whether or not Amylin…

Jon C. Ogg | Jun 5, 2012 at 8:16 AM EDT

Is Amylin Already At Full M&A Value Even Before It Is Announced? (AMLN, AZN, SNY, MRK, BMY, PFE)

Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) is back in the rumor mill as far as a buyout, but this time the…

Jon C. Ogg | May 18, 2012 at 7:47 AM EDT

An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABPI, BMY, CLDX, CYTR, CYCC, GALE, EXEL, GNBT, GHDX, IMGN, MYGN, NKTR, NLNK, ONXX, OPTR, PCYC, SGEN, SNSS, SNTA)

We are now just about two weeks away from the king of biotech and pharma events in cancer treatments. The 2012…

Jon C. Ogg | Apr 27, 2012 at 9:15 AM EDT

One Big Disbelief of an Amylin Buyout… Worth Only $12 Per Share? (AMLN, BMY, MRK, AZN, SNY, PFE, NVO)

Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) is supposed to be acquired by a larger drug company. It is one of the…

Paul Ausick | Apr 26, 2012 at 4:06 PM EDT

24/7 Wall St. Closing Bell (GD, ABB, HOG, COP, S, ALU, MO, PEP, TLAB, XOM, AET, BMY, BG, JBLU, LIZ, MJN, REGN, SWY, SWC, TASR, UPS, YNDX, NRGY, SPH, LEAP, AKAM)

Markets opened a few ticks lower this morning after a poor report on new claims for unemployment benefits in the…

Jon C. Ogg | Apr 23, 2012 at 2:54 PM EDT

What’s A Better Buyout: Ardea or Amylin? (RDEA, AMLN, AZN, BMY, MRK)

Ardea Biosciences, Inc. (NASDAQ: RDEA) is soaring today on news that AstraZeneca PLC (NYSE: AZN) is paying about $1.26 billion to…

Paul Ausick | Apr 23, 2012 at 7:59 AM EDT

Amylin Seeks a Buyer (AMLN, CS, GS, BMY, SNY, LLY, AZN, MRK)

Diabetes drug maker Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) has hired bankers and lawyers to help the company find a buyer.…

Douglas A. McIntyre | Apr 19, 2012 at 12:09 PM EDT

Executive Pay Up 14% in 2011

The data is from a major union, and, therefore, may have a bias against chief executives. Numbers can be bent.…

Douglas A. McIntyre | Apr 5, 2012 at 6:52 AM EDT

Media Digest (4/5/2012) Reuters, WSJ, NYT, FT, Bloomberg

After legal issues slowed their progress last year, foreclosures are about to increase. (Reuters) Time Warner Cable (NYSE: TWC) may…

1 … 30 31 32 33 34 … 40

Bristol Myers Squibb : BMY

All Bristol Myers Squibb Articles

Top 10 U.S. Drugs for 2012 First Quarter

Abbott Labs Stung by Foreign Exchange Rate

Looking for the Next Biotech Buyout After Two Drug and Biotech Deals

Finding the Next Biotech M&A Targets (HGSI, GSK, AMLN, BMY, VRTX, CELG, CBST, AMRN, DNDN, BMRN, VVUS, ARNA, PCYC, VICL, MDGN, AFFX, THRX, RIGL)

Which Biotechs Could Be Next M&A Targets (AMLN, BMY, VRTX, CELG, CBST, AMRN, BMRN, VVUS, ARNA, PCYC, AFFX, THRX, RIGL, HGSI, GSK, DNDN)

The Next Mergers & Buyouts For 2012

The Long Buyout Valuation of Amylin… A Higher Price Yet To Come?

Is Amylin Already At Full M&A Value Even Before It Is Announced? (AMLN, AZN, SNY, MRK, BMY, PFE)

An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABPI, BMY, CLDX, CYTR, CYCC, GALE, EXEL, GNBT, GHDX, IMGN, MYGN, NKTR, NLNK, ONXX, OPTR, PCYC, SGEN, SNSS, SNTA)

One Big Disbelief of an Amylin Buyout… Worth Only $12 Per Share? (AMLN, BMY, MRK, AZN, SNY, PFE, NVO)

24/7 Wall St. Closing Bell (GD, ABB, HOG, COP, S, ALU, MO, PEP, TLAB, XOM, AET, BMY, BG, JBLU, LIZ, MJN, REGN, SWY, SWC, TASR, UPS, YNDX, NRGY, SPH, LEAP, AKAM)

What’s A Better Buyout: Ardea or Amylin? (RDEA, AMLN, AZN, BMY, MRK)

Amylin Seeks a Buyer (AMLN, CS, GS, BMY, SNY, LLY, AZN, MRK)

Executive Pay Up 14% in 2011

Media Digest (4/5/2012) Reuters, WSJ, NYT, FT, Bloomberg

Live Nasdaq Composite: Markets Take Breather After Impressive Q2 Showing on Easing Oil Outlook

Pepsi Price Prediction: The Case for 20%+ Upside

Micron Hit With Price-Fixing Lawsuit: Real Collusion or Simple Supply and Demand?

One Roth Conversion at 63 Can Spike Your Medicare Premium Two Years Later. Here’s the Cliff.

One Roth Conversion at 63 Can Spike Your Medicare Premium Two Years Later. Here's the Cliff.

The 11-Year Tax Window Most Retirees Miss Between 62 and 73

Pepsi Price Prediction: The Case for 20%+ Upside

Micron Hit With Price-Fixing Lawsuit: Real Collusion or Simple Supply and Demand?

Bristol Myers Squibb : BMY

All Bristol Myers Squibb Articles

Top 10 U.S. Drugs for 2012 First Quarter

Abbott Labs Stung by Foreign Exchange Rate

Looking for the Next Biotech Buyout After Two Drug and Biotech Deals

Finding the Next Biotech M&A Targets (HGSI, GSK, AMLN, BMY, VRTX, CELG, CBST, AMRN, DNDN, BMRN, VVUS, ARNA, PCYC, VICL, MDGN, AFFX, THRX, RIGL)

Which Biotechs Could Be Next M&A Targets (AMLN, BMY, VRTX, CELG, CBST, AMRN, BMRN, VVUS, ARNA, PCYC, AFFX, THRX, RIGL, HGSI, GSK, DNDN)

The Next Mergers & Buyouts For 2012

The Long Buyout Valuation of Amylin… A Higher Price Yet To Come?

Is Amylin Already At Full M&A Value Even Before It Is Announced? (AMLN, AZN, SNY, MRK, BMY, PFE)

An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABPI, BMY, CLDX, CYTR, CYCC, GALE, EXEL, GNBT, GHDX, IMGN, MYGN, NKTR, NLNK, ONXX, OPTR, PCYC, SGEN, SNSS, SNTA)

One Big Disbelief of an Amylin Buyout… Worth Only $12 Per Share? (AMLN, BMY, MRK, AZN, SNY, PFE, NVO)

24/7 Wall St. Closing Bell (GD, ABB, HOG, COP, S, ALU, MO, PEP, TLAB, XOM, AET, BMY, BG, JBLU, LIZ, MJN, REGN, SWY, SWC, TASR, UPS, YNDX, NRGY, SPH, LEAP, AKAM)

What’s A Better Buyout: Ardea or Amylin? (RDEA, AMLN, AZN, BMY, MRK)

Amylin Seeks a Buyer (AMLN, CS, GS, BMY, SNY, LLY, AZN, MRK)

Executive Pay Up 14% in 2011

Media Digest (4/5/2012) Reuters, WSJ, NYT, FT, Bloomberg

Live Nasdaq Composite: Markets Take Breather After Impressive Q2 Showing on Easing Oil Outlook

Pepsi Price Prediction: The Case for 20%+ Upside

Micron Hit With Price-Fixing Lawsuit: Real Collusion or Simple Supply and Demand?

One Roth Conversion at 63 Can Spike Your Medicare Premium Two Years Later. Here’s the Cliff.

Featured Reads

One Roth Conversion at 63 Can Spike Your Medicare Premium Two Years Later. Here's the Cliff.

The 11-Year Tax Window Most Retirees Miss Between 62 and 73